[PSA] PeptideMeter results are area% by default and people keep forgetting
Putting this at the top of the board where it belongs: PeptideMeter results are area% by default and people keep forgetting.
The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.
Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.
Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.
It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.
Switching from semaglutide, since three people asked in this thread alone.
There is no published dose equivalence between the two. The conversion tables that circulate are somebody’s arithmetic, not data. What people report here is that the first month after a switch is often flat, that the appetite effect feels differently shaped rather than simply stronger, and that starting at the bottom of the ladder again is the common approach.
None of that is a recommendation. It is what the threads say, and the threads are not a clinic.
This is the fifth "should I go up" post today and they are all welcome — but no member here can answer it for you.
[deleted]
What is the waist doing? That is usually the number still moving during a scale stall.
Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.
The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.
Yes — 10mg being a genuine landing place for a lot of people is underrated. There is no medal for 15.
The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.
Went 10 to 12.5 on the calendar and had the worst fortnight of the whole run. Dropped back to 10 and everything settled.
the nausea profile is genuinely gentler than people expect coming from sema
5kg over 29 weeks, never went past 10mg, and reflux stayed mild the whole way. Posting because the loud threads are all 15mg.
the appetite effect is blunter than sema, in a good way, most weeks
Yes. I stepped to 12.5 because the calendar said so, not because anything needed fixing, and I regretted it for a fortnight.
Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.
The 21% figure is a 72-week mean on the highest arm. Quoting it as what someone should expect by week 45 is not a fair reading.
Same experience with the appetite effect being flatter across the week rather than front-loaded.
zepbound and mounjaro are the same compound with different labels
Came off sema and onto tirz with a two-week gap. The first month was flat and I assumed I had made a mistake. Month two it moved.